| Serial Number | 79355609 |
| Word Mark | SOM BIOTECH |
| Filing Date | Wednesday, July 20, 2022 |
| Status | 700 - REGISTERED |
| Status Date | Tuesday, June 4, 2024 |
| Registration Number | 7404026 |
| Registration Date | Tuesday, June 4, 2024 |
| Mark Drawing | 5 - Drawing with word(s) / letter(s) / number(s) in Stylized form |
| Published for Opposition Date | Tuesday, March 19, 2024 |
| Description of Mark | The mark consists of the words "SOM BIOTECH" written in capital stylized letters. The word "SOM" is depicted in red, grey and black and it is represented in bigger letters than the word "BIOTECH", which is located under "SOM" and it is represented in grey in a smaller size. |
| Goods and Services | Pharmaceutical preparations for the prevention of diseases of the nervous system; pharmaceutical preparations for treating metabolic disorders; chemical preparations for pharmaceutical purposes for the treatment of diseases of the nervous system, metabolic disorders, malignant tumors, for activating cellular function, for cardiovascular and cerebrovascular diseases, for the treatment of Parkinson's disease, for the prevention of diseases of the respiratory system, for gastro-intestinal disorders, for the treatment of infectious diseases, for movement disorders, for oncologic diseases, for immune system diseases, for skeletal muscular diseases, for hormone disorders, for skin diseases, for ophthalmologic disease, for gynecological diseases, for hematological diseases and for pediatric diseases; pharmaceutical agents affecting metabolism; pharmaceutical preparations for treating malignant tumors; pharmaceutical preparations for activating cellular function; medicines for the treatment of cardiovascular and cerebrovascular diseases; pharmaceutical preparations for the treatment of parkinson's disease; pharmaceutical preparations for the prevention of diseases of the respiratory system; pharmaceutical preparations for the treatment of rare diseases being hereditary movement disorders such as Huntington disease, Tourette disease, tardive dyskinesia, hereditary muscular dystrophies, hereditary metabolic disorders, hereditary neurological diseases, amyloidosis, rare neurodegenerative diseases, myotonic dystrophy, spinal muscular atrophy, idiopathic pulmonary fibrosis, multiple sclerosis, neurofibromatosis, Acute Flaccid Myelitis, Devic's syndrome, rare cancers, neuropathic pain, ELA and diabetes; pharmaceuticals, for use in the field of treatment of hereditary diseases being Huntington's Disease, Phenylketonuria, Tay Sachs, Duchenne Muscular Dystrophy, Dystrophinopathies, GM2 gangliosidoses, Niemann Pick Disease, hereditary amyloidosis, hereditary Parkinson's Disease, adrenoleukodystrophy, Dravet syndrome, Batten disease, Fragile X syndrome, Friedrich Ataxia, Lennox Gastaut, Gaucher disease, cystic fibrosis, acute myeloid leukemia, sickle cell disease; pharmaceutical preparations for the treatment of gastro-intestinal disorders; pharmaceutical products for the treatment of infectious diseases; pharmaceuticals, for use in treatment of movement disorders; pharmaceutical preparations for use in oncology; pharmaceuticals for the treatment of immune system disease; pharmaceuticals, for use in the treatment of skeletal muscular diseases; pharmaceuticals, for use in the treatment of hormone disorders; pharmaceuticals, for use in the treatment of skin diseases; pharmaceutical preparations for use in ophthalmology; pharmaceuticals, for use in the treatment of gynaecological diseases; pharmaceuticals, for use in the treatment of haematological diseases; pharmaceuticals, for use in the treatment of paediatric diseases; reagents for use in medical genetic testing; clinical medical reagents; drug delivery agents consisting of compounds that modulate delivery of a wide range of pharmaceuticals; pharmaceutical preparations, namely, drug detoxifying agents; central nervous system stimulants; respiratory stimulants; cardiovascular drugs used in treating congestive heart failure (CHF); preparations for detecting genetic predispositions for medical purposes; cells for medical use; tumor suppressing agents; pharmaceutical preparations for treatment of tumors, namely, tumor antigens; biopharmaceuticals for the treatment of cancer |
| Indication of Colors claimed | The color(s) black, grey and red is/are claimed as a feature of the mark. |
| NOT AVAILABLE | "BIOTECH" |
| Goods and Services | Clinical research in the field of development of drugs discovered through artificial intelligence technology; biological research; chemical technological research in the field of development of drugs discovered through artificial intelligence technology; biomedical research services; research services in the fields of computation chemistry; medical and pharmacological research services in the field of drug discovery and development through artificial intelligence technology; research and development of vaccines and medicines; research and development in the field of microorganisms and cells; stem cell research services; research in the field of artificial intelligence technology; development of pharmaceutical preparations and medicines; implementation of preclinical trials, namely, conducting research and clinical trials for others relating to medical devices and pharmaceuticals in the field of oncology, neurology, metabolic diseases, respiratory diseases, cardiovascular diseases, ophthalmologic diseases, gastro-intestinal diseases, dermatological diseases, musculoskeletal diseases, gynaecological diseases, paediatric diseases, infectious diseases, movement disorders, hormone disorders, immune system disorders, neurodegenerative diseases; clinical trials, namely, conducting research and clinical trials for others relating to medical devices and pharmaceuticals in the field of oncology, neurology, metabolic diseases, respiratory diseases, cardiovascular diseases, ophthalmologic diseases, gastro-intestinal diseases, dermatological diseases, musculoskeletal diseases, gynaecological diseases, paediatric diseases, infectious diseases, movement disorders, hormone disorders, immune system disorders, neurodegenerative diseases; providing scientific information about the results of clinical trials for pharmaceutical products; consultancy pertaining to pharmacology; consultancy relating to research in the field of pharmacogenetics; consultancy relating to pharmaceutical research and development; chemistry consultation; providing information on the subject of scientific research in the field of biochemistry and biotechnology; laboratory analysis in the field of chemistry; design and development of medical technology; information technology (IT) consulting services for the pharmaceutical and healthcare industries; design and development of computer software for use with medical technology; design and development in relation to artificial intelligence technology; drug repositioning research; drug combination research |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, November 28, 2022 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, November 28, 2022 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | SOM INNOVATION BIOTECH, S.A. |
| Party Type | 30 - Original Registrant |
| Legal Entity Type | 85 - NOT AVAILABLE |
| Address | ES |
| Party Name | SOM INNOVATION BIOTECH, S.A. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 85 - NOT AVAILABLE |
| Address | ES |
| Party Name | SOM INNOVATION BIOTECH, S.A. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 85 - NOT AVAILABLE |
| Address | ES |
| Event Date | Event Description |
| Friday, November 25, 2022 | LIMITATION FROM ORIGINAL APPLICATION ENTERED |
| Thursday, November 17, 2022 | SN ASSIGNED FOR SECT 66A APPL FROM IB |
| Monday, November 28, 2022 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Friday, December 2, 2022 | APPLICATION FILING RECEIPT MAILED |
| Friday, May 5, 2023 | ASSIGNED TO EXAMINER |
| Tuesday, May 16, 2023 | NON-FINAL ACTION WRITTEN |
| Wednesday, May 17, 2023 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Monday, June 26, 2023 | NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW |
| Thursday, June 29, 2023 | NON-FINAL ACTION WRITTEN |
| Friday, June 30, 2023 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Saturday, August 5, 2023 | REFUSAL PROCESSED BY MPU |
| Saturday, August 5, 2023 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Monday, August 28, 2023 | REFUSAL PROCESSED BY IB |
| Wednesday, January 10, 2024 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Wednesday, January 10, 2024 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Wednesday, January 10, 2024 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Wednesday, January 10, 2024 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Wednesday, January 10, 2024 | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS |
| Wednesday, January 10, 2024 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Thursday, February 1, 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Thursday, February 1, 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Friday, February 2, 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Wednesday, February 14, 2024 | EXAMINERS AMENDMENT -WRITTEN |
| Wednesday, February 14, 2024 | EXAMINERS AMENDMENT E-MAILED |
| Wednesday, February 14, 2024 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Wednesday, February 14, 2024 | EXAMINER'S AMENDMENT ENTERED |
| Wednesday, February 14, 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, February 14, 2024 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Wednesday, February 14, 2024 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Wednesday, February 14, 2024 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Wednesday, February 28, 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Wednesday, February 28, 2024 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, March 19, 2024 | PUBLISHED FOR OPPOSITION |
| Tuesday, June 4, 2024 | REGISTERED-PRINCIPAL REGISTER |
| Tuesday, June 4, 2024 | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
| Tuesday, March 19, 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Wednesday, April 17, 2024 | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB |
| Wednesday, April 17, 2024 | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB |
| Tuesday, May 7, 2024 | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB |